586 related articles for article (PubMed ID: 16493658)
21. RAIDD expression is impaired in multidrug resistant osteosarcoma cell lines.
Yang C; Hornicek FJ; Wood KB; Schwab JH; Mankin H; Duan Z
Cancer Chemother Pharmacol; 2009 Aug; 64(3):607-14. PubMed ID: 19125251
[TBL] [Abstract][Full Text] [Related]
22. Reversal of multidrug resistance by two nordihydroguaiaretic acid derivatives, M4N and maltose-M3N, and their use in combination with doxorubicin or paclitaxel.
Chang CC; Liang YC; Klutz A; Hsu CI; Lin CF; Mold DE; Chou TC; Lee YC; Huang RC
Cancer Chemother Pharmacol; 2006 Nov; 58(5):640-53. PubMed ID: 16544145
[TBL] [Abstract][Full Text] [Related]
23. Combined treatment of P-gp-positive L1210/VCR cells by verapamil and all-trans retinoic acid induces down-regulation of P-glycoprotein expression and transport activity.
Sulová Z; Macejová D; Seres M; Sedlák J; Brtko J; Breier A
Toxicol In Vitro; 2008 Feb; 22(1):96-105. PubMed ID: 17920233
[TBL] [Abstract][Full Text] [Related]
24. [Restorative effect of quercetin on subcellular distribution of daunorubicin in multidrug resistant leukemia cell lines K562/ADM and HL-60/ADM].
Cai X; Chen FY; Han JY; Gu CH; Zhong H; Ouyang RR
Ai Zheng; 2004 Dec; 23(12):1611-5. PubMed ID: 15601547
[TBL] [Abstract][Full Text] [Related]
25. The activity of Selol in multidrug-resistant and sensitive human leukemia cells.
Suchocki P; Misiewicz I; Skupinska K; Waclawek K; Fijalek Z; Kasprzycka-Guttman T
Oncol Rep; 2007 Oct; 18(4):893-9. PubMed ID: 17786352
[TBL] [Abstract][Full Text] [Related]
26. Antimultidrug-resistant effect and mechanism of a novel CA-4 analogue MZ3 on leukemia cells.
Xu D; Fang L; Zhu Q; Hu Y; He Q; Yang B
Pharmazie; 2008 Jul; 63(7):528-33. PubMed ID: 18717489
[TBL] [Abstract][Full Text] [Related]
27. Mechanisms of resistance to ansamycin antibiotics in human breast cancer cell lines.
Benchekroun MN; Schneider E; Safa AR; Townsend AJ; Sinha BK
Mol Pharmacol; 1994 Oct; 46(4):677-84. PubMed ID: 7969046
[TBL] [Abstract][Full Text] [Related]
28. Cytotoxicity studies of some novel fluoro acridone derivatives against sensitive and resistant cancer cell lines and their mechanistic studies.
Rajendra Prasad VV; Peters GJ; Lemos C; Kathmann I; Mayur YC
Eur J Pharm Sci; 2011 Jul; 43(4):217-24. PubMed ID: 21565270
[TBL] [Abstract][Full Text] [Related]
29. Cytotoxicity and cellular uptake of doxorubicin and its formamidine derivatives in HL60 sensitive and HL60/MX2 resistant cells.
Kik K; Wasowska-Lukawska M; Oszczapowicz I; Szmigiero L
Anticancer Res; 2009 Apr; 29(4):1429-33. PubMed ID: 19414398
[TBL] [Abstract][Full Text] [Related]
30. Establishment of cisplatin-resistant variants of human neuroblastoma cell lines, TGW and GOTO, and their drug cross-resistance profiles.
Iwasaki I; Sugiyama H; Kanazawa S; Hemmi H
Cancer Chemother Pharmacol; 2002 Jun; 49(6):438-44. PubMed ID: 12107547
[TBL] [Abstract][Full Text] [Related]
31. [Altered subcellular distribution of daunorubicin in the non-P-glycoprotein-mediated multidrug-resistant cell line HL-60/ADR].
Gong Y; Wang Y; Chen F; Han J; Shao N; Fang Z; Ouyang R
Zhonghua Xue Ye Xue Za Zhi; 2000 Jun; 21(6):309-11, 2. PubMed ID: 11876999
[TBL] [Abstract][Full Text] [Related]
32. Altered expression of proliferation-inducing and proliferation-inhibiting genes might contribute to acquired doxorubicin resistance in breast cancer cells.
Saleh EM; El-Awady RA; Abdel Alim MA; Abdel Wahab AH
Cell Biochem Biophys; 2009; 55(2):95-105. PubMed ID: 19593673
[TBL] [Abstract][Full Text] [Related]
33. A new apoptosis inhibitor, CIAPIN1 (cytokine-induced apoptosis inhibitor 1), mediates multidrug resistance in leukemia cells by regulating MDR-1, Bcl-2, and Bax.
Li X; Hong L; Zhao Y; Jin H; Fan R; Du R; Xia L; Luo G; Fan D
Biochem Cell Biol; 2007 Dec; 85(6):741-50. PubMed ID: 18059532
[TBL] [Abstract][Full Text] [Related]
34. Immunotoxin resistance in multidrug resistant cells.
McGrath MS; Rosenblum MG; Philips MR; Scheinberg DA
Cancer Res; 2003 Jan; 63(1):72-9. PubMed ID: 12517780
[TBL] [Abstract][Full Text] [Related]
35. Correlation between expression of mdr-1 gene and oncogenes in human promyelocytic leukemic HL60 cell line and sublines.
Zhou WD; Zhang HQ; Fang M; Xue SB
Zhongguo Yao Li Xue Bao; 1996 Sep; 17(5):471-3. PubMed ID: 9863178
[TBL] [Abstract][Full Text] [Related]
36. Reversal of multidrug resistance of cancer cells in vitro: modification of drug resistance by selected carotenoids.
Gyémánt N; Tanaka M; Molnár P; Deli J; Mándoky L; Molnár J
Anticancer Res; 2006; 26(1A):367-74. PubMed ID: 16475720
[TBL] [Abstract][Full Text] [Related]
37. Identification of 14-3-3sigma as a contributor to drug resistance in human breast cancer cells using functional proteomic analysis.
Liu Y; Liu H; Han B; Zhang JT
Cancer Res; 2006 Mar; 66(6):3248-55. PubMed ID: 16540677
[TBL] [Abstract][Full Text] [Related]
38. Lysosomal accumulation of drugs in drug-sensitive MES-SA but not multidrug-resistant MES-SA/Dx5 uterine sarcoma cells.
Wang E; Lee MD; Dunn KW
J Cell Physiol; 2000 Aug; 184(2):263-74. PubMed ID: 10867652
[TBL] [Abstract][Full Text] [Related]
39. Cell-specific modulation of drug resistance in acute myeloid leukemic blasts by diphtheria fusion toxin, DT388-GMCSF.
Frankel AE; Hall PD; McLain C; Safa AR; Tagge EP; Kreitman RJ
Bioconjug Chem; 1998; 9(4):490-6. PubMed ID: 9667951
[TBL] [Abstract][Full Text] [Related]
40. Bioreductive activation of mitoxantrone by NADPH cytochrome P450 reductase. Implications for increasing its ability to inhibit the growth of sensitive and multidrug resistant leukaemia HL60 cells.
Kostrzewa-Nowak D; Paine MJ; Korytowska A; Serwatka K; Piotrowska S; Wolf CR; Tarasiuk J
Cancer Lett; 2007 Jan; 245(1-2):252-62. PubMed ID: 16574318
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
